Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:endPoint |
overall response rate
|
| gptkbp:enrollment |
97 patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
CARTITUDE-1 trial
|
| gptkbp:location |
gptkb:China
gptkb:United_States |
| gptkbp:NCT_number |
NCT03548207
|
| gptkbp:patient_population |
relapsed or refractory multiple myeloma
|
| gptkbp:period |
Phase 1b/2
|
| gptkbp:primary_investigator |
Jesus G. Berdeja
|
| gptkbp:registration |
gptkb:ClinicalTrials.gov
|
| gptkbp:result |
high response rate
manageable safety profile |
| gptkbp:results_published_in |
gptkb:New_England_Journal_of_Medicine
gptkb:The_Lancet |
| gptkbp:sponsor |
gptkb:Janssen
gptkb:Legend_Biotech |
| gptkbp:startDate |
2018
|
| gptkbp:studies |
gptkb:ciltacabtagene_autoleucel
multiple myeloma |
| gptkbp:therapy_type |
gene therapy
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|